MediPharm Labs Enters Denmark Health-related Cannabis Marketplace, Secures New White-Label Provide Clients

bunch of red fruits

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a international leader in specialized, investigation-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative items, right now announced it will provide cannabis concentrate items in Denmark to two new health-related cannabis consumers beneath two separate white-label agreements. These consumers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ 1st provide agreements for the export of completed items to Denmark.

Denmark granted individuals legal access to cannabis-primarily based medicinal items two years ago as aspect of a 4-year pilot plan. The plan supplies individuals with secure item access and national wellness authorities with patient information that they can use to recognize usage and efficacy. According to details complied by New Frontier Information and the Danish Ministry of Wellness, more than two,one hundred individuals (mostly ladies involving the ages of 42-64) received cannabis-primarily based medicinal items from 429 prescribing physicians beneath this plan in 2019.

“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the international cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent an additional step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related marketplace with new and revolutionary health-related cannabis focused items positions us for further development in Europe and adds to MediPharm Labs all-crucial physique of expertise that we are leveraging to improve the style of our formulations for individuals and customers everywhere.”

Below the agreements, 1 which has an initial two-year term and the second a 1-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil items that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its consumers to commence in October 2020, pending regulatory approval by applicable wellness authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured quite a few pretty desirable domestic and international provide agreements with higher high-quality partners, now like new consumers in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new business enterprise wins are a clear and crucial validation of our selection to make a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production beneath all of these agreements.”

MediPharm Labs Australia received its Great Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May well 2020, which enables it to sell cannabis APIs and completed items to nations across the EU, like Denmark. The Firm entered into its 1st European white-label cannabis provide agreement that identical month with Therismos Restricted.

About Denmark’s Health-related Cannabis Marketplace

Denmark launched its 4-year health-related cannabis pilot plan on January 1st, 20181. Post-harvest Great Manufacturing Processes (GMP) is needed for distribution of health-related cannabis items in Denmarktwo.

By means of the plan, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 locations: discomfort triggered by several sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an substantial assessment of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative items using a Great Manufacturing Practices certified facility with ISO regular constructed clean rooms. MediPharm Labs has invested in an professional, investigation-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 key extraction lines for delivery of pure, trusted and precision -dosed cannabis items for its consumers. By means of its wholesale and white label platforms, they formulate, customer-test, method, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based items to domestic and international markets. As a international leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional details, please make contact with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E mail: [email protected]
Site: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot Plan. Retrieved: https://laegemiddelstyrelsen.dk/en/specific/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Health-related Cannabis Marketplace in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-health-related-cannabis-marketplace-in-denmark-europe/80721/
three The Danish Health-related Cannabis Pilot Programme: Placing the Patient Initially. Retrieved: https://www.healtheuropa.eu/the-danish-health-related-cannabis-pilot-programme-placing-the-patient-1st/92991/

CAUTIONARY NOTE Relating to FORWARD-Hunting Info:

This news release consists of “forward-searching information” and “forward-searching statements” (collectively, “forward-searching statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-searching statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that requires discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (normally but not often employing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that particular actions, events or benefits “may” or “could”, “would”, “might” or “will” be taken to happen or be accomplished) are not statements of historical truth and might be forward-searching statements. In this news release, forward-searching statements relate to, amongst other items, the thriving overall performance of the agreements and shipping of items thereunder as planned further development in Europe and enhancing the style of formulations. Forward-searching statements are necessarily primarily based upon a quantity of estimates and assumptions that, whilst regarded affordable, are topic to identified and unknown dangers, uncertainties, and other components which might result in the actual benefits and future events to differ materially from these expressed or implied by such forward-searching statements. Such components involve, but are not restricted to: common business enterprise, financial, competitive, political and social uncertainties the inability of MediPharm Labs to get sufficient financing the delay or failure to acquire regulatory approvals and other components discussed in MediPharm Labs’ filings, accessible on the SEDAR web site at www.sedar.com. There can be no assurance that such statements will prove to be correct, as actual benefits and future events could differ materially from these anticipated in such statements. Accordingly, readers should really not spot undue reliance on the forward-searching statements and details contained in this news release. Except as needed by law, MediPharm Labs assumes no obligation to update the forward-searching statements of beliefs, opinions, projections, or other components, should really they transform.

Primary Logo

If You Liked This Post Click To Share

.mobile_tx{show: none}
#ax1x{
font-size: 1.1em
font-weight: bold
line-height: 1.five
clear:each
margin: 0px 0px 20px 1% !crucial
min-height: four.5em
text-transform: uppercase
padding: .25em 10px
position: relative
width: 98%
float: left
}
.subsequent-pg {
height: 85px !crucial
width: one hundred%
border-best-left-radius: 3px
border-bottom-left-radius: 3px
background-colour: #e5192c
background-image: url(‘/wp-content material/themes/mh-magazine/pictures/international-just after.png’) !crucial
background-repeat: no-repeat
background-position: ideal center
background-size: auto one hundred%
overflow: hidden
box-sizing: border-box
margin-bottom: 0px
margin-best: 10px
position: relative
padding-left: 100px
}
.subsequent-pg::just before {
width: 45px !crucial
height: 85px !crucial
show: block
content material: “”
width: 32px
height: 64px
background-image: url(‘/wp-content material/themes/mh-magazine/pictures/international-just before.png’) !crucial
background-repeat: no-repeat
background-position: ideal center
background-size: auto one hundred%
position: absolute
left: -4px
best: 0px
}
.action-txt {
text-transform: uppercase
margin: 12px
line-height: 61px
text-align: left
font-size: 36px
background-repeat: no-repeat
background-position: ideal center
background-size: 26px 18px
colour: #FFF
float: left
font-weight: bold
font-family members: “Open Sans”,sans-serif !crucial
width: 78%
show: inline-block
text-align: center
}
@media (max-width: 768px){
.mobile_tx{show: block}
.desktop_tx{show: none}
.pps-slider-nav .pps-subsequent {
text-align: center
position: static
padding: 5px 20px
float: left
width: one hundred%
box-sizing: border-box
}
.pps-subsequent .subsequent-write-up-web page {
padding-left:
float: left
margin:
}
.subsequent-write-up-web page .action-txt {
padding-left: !crucial
text-align: center
width: 87%
box-sizing: border-box
font-size: 26px
background:
text-align: center
}
#ax1x {
padding: .25em !crucial
min-height: two.3em
width: one hundred% !crucial
margin: 0px !crucial
margin-bottom: 15px !crucial
padding-bottom: !crucial
}
}
@media (max-width: 500px){
.subsequent-write-up-web page .action-txt{
width: 75%
}
}

Latest posts